Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia

Նմանատիպ նյութեր

• Induction of AML Preleukemic Fusion Genes in HSPCs and DNA Damage Response in Preleukemic Fusion Gene Positive Samples
  ‌: Pavol Kosik, և այլն
  Հրապարակվել է: (2021-03-01)
• Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia
  ‌: Tracy Murphy, և այլն
  Հրապարակվել է: (2023-06-01)
• Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia
  ‌: Robert Puckrin, և այլն
  Հրապարակվել է: (2020-01-01)
• Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
  ‌: Victoria V. Grunwald, և այլն
  Հրապարակվել է: (2019-09-01)
• Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML
  ‌: May Chiu, և այլն
  Հրապարակվել է: (2024-10-01)